Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab study of health, physical activity, and joint outcomes in moderate or severe hemophilia A without FVIII inhibitors
ISRCTN10101701Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label trial of emicizumab in hemophilia A (3 cohorts), sponsored by Roche. Primary endpoints: Joint status over time by HEAD-US with focus on synovitis, Clinical joint status by HJHS v2.1 and 9 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ISRCTN10101701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10101701.